|1.||Gheorghiade, Mihai: 7 articles (08/2011 - 01/2007)|
|2.||Ferrari, Patrizia: 5 articles (08/2013 - 01/2007)|
|3.||Valentini, Giovanni: 5 articles (12/2009 - 01/2007)|
|4.||Sabbah, Hani N: 5 articles (12/2009 - 01/2007)|
|5.||Carminati, Paolo: 5 articles (06/2009 - 08/2003)|
|6.||Filippatos, Gerasimos S: 4 articles (12/2009 - 05/2008)|
|7.||Blair, John E A: 4 articles (12/2009 - 05/2008)|
|8.||Barassi, Paolo: 3 articles (08/2013 - 01/2007)|
|9.||Ferrandi, Mara: 3 articles (08/2013 - 01/2007)|
|10.||Gagnol, Jean-Pierre: 3 articles (04/2011 - 08/2003)|
06/01/2008 - "Istaroxime, an agent that appears to have both inotropic and lusitropic effects, improved haemodynamics when added to standard therapy in patients stabilised after admission with heart failure in HORIZON-HF. "
04/01/2011 - "The aim of present study is to assess the effect of chronic istaroxime treatment on cardiac function and heart rate variability in Bio TO.2 Syrian hamster model of progressive heart failure. "
06/01/2009 - "Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial."
05/01/2008 - "Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial."
01/22/2007 - "A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function."
10/01/2011 - "The aim of this study was to encapsulate istaroxime in a drug delivery system (DDS) that could minimize the pain perceived upon administration. "
01/22/2007 - "Istaroxime was pharmacologically active and well tolerated at doses up to 3.33 micro/kg per min. Side effects were related to gastrointestinal symptoms and injection site pain at higher doses, which dissipated within minutes after the infusion ended. "
|4.||Left Ventricular Dysfunction
|1.||Adenosine Triphosphatases (ATPase)
|2.||Calcium-Transporting ATPases (Ca2+ ATPase)
|5.||Neurotransmitter Agents (Neurotransmitter)
|6.||3- ((2- aminoethoxy)imino)androstane- 6,17- dione
|8.||Brain Natriuretic Peptide (Natrecor)